These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31511529)

  • 1. Putative link between Polo-like kinases (PLKs) and Toll-like receptor (TLR) signaling in transformed and primary human immune cells.
    El Maadidi S; Weber ANR; Motshwene P; Schüssler JM; Backes D; Dickhöfer S; Wang H; Liu X; Garcia MD; Taumer C; Soufi B; Wolz OO; Klimosch SN; Franz-Wachtel M; Macek B; Gay NJ
    Sci Rep; 2019 Sep; 9(1):13168. PubMed ID: 31511529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like kinase 1 (PLK1) is involved in toll-like receptor (TLR)-mediated TNF-α production in monocytic THP-1 cells.
    Hu J; Wang G; Liu X; Zhou L; Jiang M; Yang L
    PLoS One; 2013; 8(10):e78832. PubMed ID: 24205328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-mitotic functions of polo-like kinases in cancer cells.
    Raab CA; Raab M; Becker S; Strebhardt K
    Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188467. PubMed ID: 33171265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin 1/Toll-like receptor-induced autophosphorylation activates interleukin 1 receptor-associated kinase 4 and controls cytokine induction in a cell type-specific manner.
    Cushing L; Stochaj W; Siegel M; Czerwinski R; Dower K; Wright Q; Hirschfield M; Casanova JL; Picard C; Puel A; Lin LL; Rao VR
    J Biol Chem; 2014 Apr; 289(15):10865-10875. PubMed ID: 24567333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the Functions of Polo-Like Kinases in Mice and Their Applications as Cancer Targets with a Special Focus on Ovarian Cancer.
    Kressin M; Fietz D; Becker S; Strebhardt K
    Cells; 2021 May; 10(5):. PubMed ID: 34065956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Menendez JA
    Cell Cycle; 2011 Apr; 10(8):1295-302. PubMed ID: 21474997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IRAK4 kinase activity controls Toll-like receptor-induced inflammation through the transcription factor IRF5 in primary human monocytes.
    Cushing L; Winkler A; Jelinsky SA; Lee K; Korver W; Hawtin R; Rao VR; Fleming M; Lin LL
    J Biol Chem; 2017 Nov; 292(45):18689-18698. PubMed ID: 28924041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polo-like kinases inhibitors.
    Garuti L; Roberti M; Bottegoni G
    Curr Med Chem; 2012; 19(23):3937-48. PubMed ID: 22709006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined CpG and poly I:C stimulation of monocytes results in unique signaling activation not observed with the individual ligands.
    Arsenault RJ; Kogut MH; He H
    Cell Signal; 2013 Nov; 25(11):2246-54. PubMed ID: 23876795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress with polo-like kinase (PLK) inhibitors: a patent review (2018-present).
    Bian S; Zhang R; Nie J; Zhu M; Xie Z; Liao C; Wang Q
    Expert Opin Ther Pat; 2024 Sep; 34(9):789-806. PubMed ID: 38994687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and enzoinformatics perspectives of targeting Polo-like kinase 1 in cancer therapy.
    Shakil S; Baig MH; Tabrez S; Rizvi SMD; Zaidi SK; Ashraf GM; Ansari SA; Khan AAP; Al-Qahtani MH; Abuzenadah AM; Chaudhary AG
    Semin Cancer Biol; 2019 Jun; 56():47-55. PubMed ID: 29122685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinases in AML.
    Berg T; Bug G; Ottmann OG; Strebhardt K
    Expert Opin Investig Drugs; 2012 Aug; 21(8):1069-74. PubMed ID: 22667760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interplay between Polo kinase, LKB1-activated NUAK1 kinase, PP1βMYPT1 phosphatase complex and the SCFβTrCP E3 ubiquitin ligase.
    Banerjee S; Zagórska A; Deak M; Campbell DG; Prescott AR; Alessi DR
    Biochem J; 2014 Jul; 461(2):233-45. PubMed ID: 24785407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation of synucleins by members of the Polo-like kinase family.
    Mbefo MK; Paleologou KE; Boucharaba A; Oueslati A; Schell H; Fournier M; Olschewski D; Yin G; Zweckstetter M; Masliah E; Kahle PJ; Hirling H; Lashuel HA
    J Biol Chem; 2010 Jan; 285(4):2807-22. PubMed ID: 19889641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    Zeng Y; Li N; Liu W; Zeng M; Cheng J; Huang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2447-2460. PubMed ID: 32627077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct surfaces on Cdc5/PLK Polo-box domain orchestrate combinatorial substrate recognition during cell division.
    Almawi AW; Langlois-Lemay L; Boulton S; Rodríguez González J; Melacini G; D'Amours D; Guarné A
    Sci Rep; 2020 Feb; 10(1):3379. PubMed ID: 32099015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic analysis of the Plk-mediated phosphoregulation in eukaryotes.
    Liu Z; Ren J; Cao J; He J; Yao X; Jin C; Xue Y
    Brief Bioinform; 2013 May; 14(3):344-60. PubMed ID: 22851512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).
    Liu-Sullivan N; Zhang J; Bakleh A; Marchica J; Li J; Siolas D; Laquerre S; Degenhardt YY; Wooster R; Chang K; Hannon GF; Powers S
    Oncotarget; 2011 Dec; 2(12):1254-64. PubMed ID: 22248814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.